Kaiser Health News
At Stake in Mifepristone Case: Abortion, FDA’s Authority, and Return to 1873 Obscenity Law
Sarah Varney, KFF Health News
Mon, 25 Mar 2024 18:00:00 +0000
Lawyers from the conservative Christian group that won the case to overturn Roe v. Wade are returning to the U.S. Supreme Court on Tuesday in pursuit of an urgent priority: shutting down access to abortion pills for women across the country.
The case challenges the FDA’s regulation of mifepristone, a prescription-only drug approved in 2000 with a stellar safety record that is used in 63% of all U.S. abortions.
Viewed across decades of anti-abortion activism, the case brought by the Alliance Defending Freedom represents a “moonshot” couched in technical arguments about pharmaceutical oversight and the resuscitation of an 1873 anti-obscenity law. A victory would lay the groundwork for a de facto nationwide abortion ban.
Abortion is illegal in 14 states, but abortion pills have never been more widely available.
During the covid-19 pandemic, the FDA suspended — and later formally lifted — the requirement that patients be at a health care facility when taking mifepristone, the first of two pills used in medication abortion. Physicians can now prescribe the drug online through telemedicine and pharmacies can dispense it through the mail.
“You don’t need to be handed the pill in the office,” said Linda Prine, a family medicine physician, sitting on a couch in her Manhattan apartment answering texts and calls from patients about abortion care.
“It’s very effective,” she said. “I don’t even have medications that are 98 to 99% effective. Our blood pressure medicines aren’t effective like that.”
Prine, a co-founder of the Miscarriage and Abortion Hotline, works with other doctors operating under New York state’s shield law to prescribe and send abortion pills to people across the country. A review of Prine’s call log, stripped of personal information, showed hundreds of requests for pills from Texas, Louisiana, Tennessee, and other states where it is illegal for women to stop a pregnancy.
Anti-abortion groups unsuccessfully petitioned the FDA at least twice before, in 2002 and 2019, to revoke mifepristone’s approval and curtail its availability. But in November 2022, following its victory in overturning federal abortion rights, the Alliance Defending Freedom filed a federal lawsuit in Amarillo, Texas, claiming the FDA’s safety review of mifepristone was flawed.
U.S. District Judge Matthew Kacsmaryk, who was appointed by President Donald Trump and openly opposes abortion, ruled to invalidate the FDA’s approval of mifepristone. An appeals court later said the drug should remain available, but it reinstated restrictions, including prohibitions on telehealth prescriptions and mailing the medication. That ruling was put on hold while the Supreme Court considers the case.
The Biden administration and a manufacturer of mifepristone, Danco Laboratories, have argued in legal filings to the Supreme Court that federal judges do not have the scientific and health expertise to evaluate drug safety and that allowing them to do so undermines the FDA’s regulatory authority.
That view is supported by food and drug legal scholars who wrote in court filings that the lower courts had replaced the “FDA’s scientific and medical expertise with the courts’ own interpretations of the scientific evidence.” In doing so, they wrote, the courts “upend the drug regulatory scheme established by Congress and implemented by FDA.”
In his ruling, Kacsmaryk cited two studies purporting to show an increase in emergency room visits and a greater risk of hospitalizations from medication abortion. They were retracted in February by medical publisher Sage Perspectives. The journal said the researchers erred in their methodology and analysis of the data and invalidated the papers “in whole or in part.”
The research, supported by the Charlotte Lozier Institute, an anti-abortion group that filed a brief in the mifepristone case, “made claims that were not supported by the data,” said Ushma Upadhyay, a professor of reproductive sciences at the University of California-San Francisco.
Legal scholars say the Supreme Court’s conservative justices have demonstrated a willingness to accept discredited abortion-related health claims. Justice Samuel Alito, writing the majority opinion in Dobbs v. Jackson Women’s Health Organization, which overturned the constitutional right to abortion, cited statements about harm to maternal health presented by the state of Mississippi that contradict mainstream medical consensus.
“If this case is successful, it will be because the Supreme Court decided to ignore evidence that demonstrated mifepristone’s safety and said to a federal agency, the expert on drug safety, ‘You were wrong,’” said Rachel Rebouché, dean of Temple University Beasley School of Law.
The mifepristone case crystallizes “the politicization of science” in abortion regulation, Rebouché said. “But the stakes are getting higher as we have courts willing to strip federal agencies of their ability to make expert decisions.”
Rebouché said that if the Supreme Court overrides the FDA’s expertise in regulating a 24-year-old drug like mifepristone, anti-abortion groups, like Students for Life of America, could find judges receptive to false claims that birth control pills, intrauterine devices, emergency contraception, and other forms of hormonal birth control cause abortion. They do not, according to reproductive scientists and U.S. and international regulatory agencies.
Justice Clarence Thomas wrote in his concurring opinion in Dobbs that the Supreme Court should reconsider the 1965 decision that guaranteed a constitutional right to contraception, Griswold v. Connecticut, and decide whether to return the power to allow or regulate access to birth control to the states.
Tucked into the Alliance Defending Freedom’s filings is what scholars describe as an audacious legal strategy once on the fringes of the conservative Christian movement: an appeal to the Supreme Court’s conservative members to determine that the Comstock Act, a dormant 1873 anti-vice law, effectively bans medical and procedural abortion nationwide.
Passed at a time when the federal government did not give women the right to vote and the prevailing medical literature summed up women’s sexuality by saying that “the majority of women (happily for them) are not very much troubled with sexual feelings of any kind,” the long unenforced law carried a five-year prison sentence for anyone mailing “every article, instrument, substance, drug, medicine or thing which is advertised or described in a manner calculated to lead another to use or apply it for producing abortion.”
References to the Comstock Act appear throughout anti-abortion legal filings and rulings: Kacsmaryk wrote that the act “plainly forecloses mail-order abortion in the present”; the 5th Circuit Court of Appeals wrote if Comstock was “strictly understood” then “there is no public interest in the perpetuation of illegality”; Republican attorneys general threatened legal action against Walgreens and CVS last year citing Comstock as did anti-abortion cases in New Mexico and Texas.
“State attorneys general need to go after and prosecute those who are illegally mailing abortion drugs into their state,” said Kristan Hawkins, president of Students for Life of America.
“It’s very simple. If your state has passed a law saying that preborn human beings deserve, at the very minimum, the right not to be starved and killed,” she said, “then those who are committing those crimes and violating the federal Comstock Act by shipping chemical abortion pills over state lines, there should be consequences.”
Tracking abortion pills by mail is difficult — and that’s the point, Rebouché said.
“These more diffuse and mobile ways to terminate a pregnancy,” she said, “really threaten the control that anti-abortion advocates seek to exercise over who and where and how someone can seek an abortion.”
——————————
By: Sarah Varney, KFF Health News
Title: At Stake in Mifepristone Case: Abortion, FDA’s Authority, and Return to 1873 Obscenity Law
Sourced From: kffhealthnews.org/news/article/supreme-court-mifepristone-case-medication-abortion-fda-authority-1873-obscenity-law/
Published Date: Mon, 25 Mar 2024 18:00:00 +0000
Did you miss our previous article…
https://www.biloxinewsevents.com/a-paramedic-was-skeptical-about-this-rx-for-stopping-repeat-opioid-overdoses-then-he-saw-it-help/
Kaiser Health News
Caseworkers Coax Homeless People out of Las Vegas’ Tunnels for Treatment
SUMMARY: In Las Vegas, case manager Bryon Johnson searches the underground tunnels for homeless individuals like Jay Flanders, who suffers from health issues and substance abuse. Escaping rising housing costs and law enforcement, around 1,200 to 1,500 people live in these tunnels, which provide shelter from extreme weather but pose significant health risks, especially during monsoon season. Outreach workers emphasize the dangers of drug addiction and untreated health conditions, urging residents to seek medical care above ground. As housing costs soar, many homeless individuals, including tourists, end up in these perilous conditions, seeking cover from societal judgment and harsh weather.
The post Caseworkers Coax Homeless People out of Las Vegas’ Tunnels for Treatment appeared first on kffhealthnews.org
Kaiser Health News
In Settling Fraud Case, New York Medicare Advantage Insurer, CEO Will Pay up to $100M
SUMMARY: Independent Health Association of Buffalo and Betsy Gaffney, CEO of medical analytics firm DxID, have agreed to a settlement of up to $100 million to resolve Justice Department allegations of fraudulent Medicare billing for exaggerated or non-existent health conditions. Independent Health will pay up to $98 million, while Gaffney will contribute $2 million. Neither party admitted wrongdoing. The case was triggered by whistleblower Teresa Ross, highlighting issues of “upcoding” in Medicare Advantage plans. Ross, having faced repercussions for her allegations, will receive at least $8.2 million from the settlement. This case underscores the challenges of regulating billing practices in the Medicare system.
The post In Settling Fraud Case, New York Medicare Advantage Insurer, CEO Will Pay up to $100M appeared first on kffhealthnews.org
Kaiser Health News
Employers Press Congress To Cement Health Price Transparency Before Trump’s Return
SUMMARY: Despite regulations requiring hospitals and insurers to disclose negotiated prices for healthcare services, the impact on consumer costs remains unclear nearly four years later. While the Trump administration’s initial rules and Biden’s enhancements aimed to streamline this data, compliance is inconsistent; a 2022 audit found only 63 out of 100 hospitals met requirements. Some lawmakers proposed legislation to protect these regulations amid uncertainty about Trump’s potential return to office, but efforts fell short. Experts note the complexity of the data often leaves consumers struggling to understand their actual costs, emphasizing the need for improved transparency and enforcement to facilitate informed healthcare choices.
The post Employers Press Congress To Cement Health Price Transparency Before Trump’s Return appeared first on kffhealthnews.org
-
Our Mississippi Home7 days ago
The Meaning of the Redbird During the Holiday Season
-
News from the South - North Carolina News Feed3 days ago
Social Security benefits boosted for millions in bill headed to Biden’s desk • NC Newsline
-
Mississippi Today6 days ago
Mississippi PERS Board endorses plan decreasing pension benefits for new hires
-
Local News3 days ago
Hard Rock Hotel & Casino Biloxi Honors Veterans with Wreath-Laying Ceremony and Holiday Giving Initiative
-
Mississippi News Video4 days ago
12/19- Friday will be breezy…but FREEZING by this weekend
-
Local News3 days ago
MDOT suspends work, urges safe driving for holiday travel
-
News from the South - Missouri News Feed4 days ago
Could prime Albert Pujols fetch $1 billion in today's MLB free agency?
-
News from the South - Texas News Feed5 days ago
Amazon workers strike at facilities around the country as Teamsters seek contract